Browse studies

Find your next paid study

157 recruiting studies matching your filters

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors t…

Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed Adenocarcinoma+42 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT03866382

Phase 2

Randomized Phase II Trial of Pembrolizumab and Radiation vs. Radiation and Concurrent Chemotherapy for High-Grade T1 Bladder Cancer (PARRC Trial)

This phase II trial compares the use of pembrolizumab and radiation therapy to chemotherapy with cisplatin, gemcitabine, 5-fluorouracil or mitomycin-C and radi…

Non-Muscle Invasive Bladder Urothelial CarcinomaRecurrent Non-Muscle Invasive Bladder Urothelial CarcinomaStage I Bladder Cancer AJCC v8

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06770582

Blinded Reference Set for Multicancer Early Detection Blood Tests

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing …

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAnn Arbor Stage I Lymphoma+59 more

Phase 1

EV-PRIME: Phase Ib/II Study of Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy as a Bladder-Sparing Trimodality Therapy in Muscle Invasive Bladder Cancer

This phase Ib/II trial studies the side effects, best dose, and effectiveness of enfortumab vedotin (EV) in combination with pembrolizumab and radiation therap…

Bladder CancerMuscle-Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8+1 more

Estimated

~$10 – $5,625

University of California, San FranciscoNCT06470282

Phase 3

GAIN-BCG: Gemcitabine Alternating With INtravesical BCG Randomized Against BCG Alone for Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer

This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with no…

Recurrent Non-Muscle Invasive Bladder CarcinomaStage 0a Bladder Cancer AJCC v8Stage I Bladder Cancer AJCC v8

Estimated

~$10 – $6,250

Alliance for Clinical Trials in OncologyNCT07000084

Phase 2

Single Arm Phase II Study of Bladder Preservation With Immunoradiotherapy After a Clinically Meaningful Response to Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer (BRIGHT)

This phase II trial tests the effect of giving pembrolizumab in combination with radiation therapy after chemotherapy in preventing surgery to remove the bladd…

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8Stage IIIA Bladder Cancer AJCC v8

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07061964

Phase 1

A Pilot PET Imaging Study of [89Zr]DFO-YS5 for Detection of Cancer in Patients With Various Malignancies

This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in pa…

Bladder CancerNerve Sheath TumorNerve Sheath Tumors+9 more

Estimated

~$10 – $7,500

Robert Flavell, MD, PhDNCT07664397

Ex-Vivo Trial of En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope Device

Background: Bladder cancer is the sixth most common cancer in the United States. The way that doctors remove tumors in bladder surgeries may leave some cancer…

Bladder Cancer

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT04235764

Observational

Patient-Centered Surgical Prehabilitation

The purpose of this research is to validate the prehabilitation program which is defined as a set of interventions meant to prepare the body physically and nut…

Bladder CancerCystectomy

Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT05715684

Phase 2

A Phase II Trial of Futibatinib in Combination With Durvalumab (MEDI4736) Administered to Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer Before Cystectomy

This phase II trial tests how well the combination of futibatinib and durvalumab given before cystectomy works in treating patients with muscle-invasive bladde…

Bladder Urothelial CarcinomaMuscle Invasive Bladder CarcinomaStage II Bladder Cancer AJCC v8+1 more

Estimated

~$10 – $7,500

Yuanquan YangNCT06263153

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Diseases

Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may b…

Malignant NeoplasmsHereditary Neoplastic SyndromesKidney Cancer+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00026884

Phase 1

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Study of Investigational Agents in Combination With Enfortumab Vedotin Plus Pembrolizumab as First-Line Treatment in Participants With Locally Advanced or Metastatic Urothelial Carcinoma: KEYMAKER-U04-Substudy 04D

Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally adv…

Bladder Cancer

Estimated

~$10 – $8,750

Merck Sharp & Dohme LLCNCT07232602